Fusion antigen used as vaccine and method of making them
Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.
1. A method for making a vaccinal virus fusion antigen, comprising:
selecting a segment of a virus protein sequence that comprises at least one epitope;
synthesizing a DNA fragment encoding the selected segment of the virus protein sequence;
inserting the DNA fragment encoding the selected segment of the virus protein sequence into a Pseudomonas Exotoxin A (PE) vector to obtain a fusion gene plasmid, in which the PE vector comprises:
(i) a PE fragment comprising a binding domain and a translocation domain and is without a cytotoxic domain; and
(ii) a carboxyl terminal moiety comprising an endoplasmic reticulum retention sequence,
wherein the DNA fragment encoding the selected segment of the virus protein sequence is inserted between the PE fragment and the carboxyl terminal moiety, thereby generating a fusion gene plasmid; and
expressing the fusion gene plasmid in a host cell to obtain the vaccinal virus fusion antigen,
wherein the vaccinal virus fusion antigen comprises:
(i) the PE fragment;
(ii) the selected segment of the virus protein sequence; and
(iii) the carboxyl terminal moiety comprising the endoplasmic reticulum retention sequence.
2. The method of claim 1 , wherein the carboxyl terminal moiety comprises the amino acid sequence of SEQ ID NO: 110.
3. The method of claim 2 , wherein the virus antigen is selected from an infectious virus that is contagious to an animal species.
4. The method of claim 2 , wherein the virus protein sequence comprises porcine reproductive and respiratory syndrome virus (PRRSV) ORF7.
5. The method of claim 2 , wherein the host cell is at least one selected from E. coli .
6. The method of claim 2 , wherein the PE fragment comprises domains Ia, II and Ib, and the DNA fragment encoding the selected segment of the virus protein sequence is inserted at the 3′ end of the domain Ib.
7. A method for making a vaccinal virus fusion antigen, comprising:
selecting a segment of a virus protein sequence that comprises at least one epitope;
synthesizing a DNA fragment encoding the selected segment of the virus protein sequence;
inserting the DNA fragment encoding the selected segment of the virus protein sequence into a Pseudomonas Exotoxin A (PE) vector to obtain a fusion gene plasmid, in which the PE vector comprises:
(i) a PE fragment comprising a binding domain and a translocation domain and is without a cytotoxic domain; and
(ii) a carboxyl terminal moiety comprising the amino acid sequence of SEQ ID NO: 112,
wherein the DNA fragment encoding the selected segment of the virus protein sequence is inserted between the PE fragment and the carboxyl terminal moiety, thereby generating a fusion gene plasmid; and
expressing the fusion gene plasmid in a host cell to obtain the vaccinal virus fusion antigen,
wherein the vaccinal virus fusion antigen comprises:
(i) the PE fragment;
(ii) the selected segment of the virus protein sequence; and
(iii) the carboxyl terminal moiety comprising the amino acid sequence of SEQ ID NO: 112.
8. The method of claim 7 , wherein the virus protein sequence comprises a porcine reproductive and respiratory syndrome virus (PRRSV) protein selected from the group consisting of ORF7 and ORF1b.
9. The method of claim 7 , wherein the virus protein sequence comprises PRRSV ORF7 protein.
10. The method of claim 7 , wherein the virus protein sequence comprises PRRSV ORF1b protein.
11. A method for making a vaccinal virus fusion antigen, comprising:
selecting a segment of a virus protein sequence that comprises at least one epitope;
synthesizing a DNA fragment encoding the selected segment of the virus protein sequence;
inserting the DNA fragment encoding the selected segment of the virus protein sequence into a Pseudomonas Exotoxin A (PE) vector to obtain a fusion gene plasmid, in which the PE vector comprises:
(i) a PE fragment comprising a binding domain and a translocation domain and is without a cytotoxic domain; and
(ii) a carboxyl terminal moiety comprising the amino acid sequence of SEQ ID NO: 110 or 111,
wherein the DNA fragment encoding the selected segment of the virus protein sequence is inserted between the PE fragment and the carboxyl terminal moiety, thereby generating a fusion gene plasmid; and
expressing the fusion gene plasmid in a host cell to obtain the vaccinal virus fusion antigen;
wherein the vaccinal virus fusion antigen comprises:
(i) the PE fragment;
(ii) the selected segment of the virus protein sequence; and
(iii) the carboxyl terminal moiety comprising the amino acid sequence of SEQ ID NO: 110 or 111.